100% penetrance of HDAC2, HDAC4, HDAC10 and SIRT3 in glioma (Figure 7A); HDAC2, HDAC9, HDAC10, SIRT3, SIRT5, SIRT6, SIRT7 in head and neck cancer (Figure 7B); HDAC10, SIRT3, SIRT5 in liver cancer (Figure 7C); HDAC1, HDAC10, SIRT6, SIRT7 in lung cancers (Figure 7D); HDAC1, HDAC2, HDAC4 in lymphoma (Figure 7E); HDAC1, HDAC2, HDAC10, SIRT3, SIRT5, SIRT6 in melanoma (Figure 8A); HDAC9, HDAC10, SIRT3, SIRT6, SIRT7 in ovarian cancer (Figure 8B); while HDAC1, HDAC10, SIRT3, SIRT6 in pancreatic cancer (Figure 8C). Here, SIRT7 is linked to ovarian carcinoma.